Advancing Cancer Care with New Diagnostic Tools

Episode Summary

Executive Summary: Andre DeFusco of Synvenio argues that liquid biopsy is becoming a practical, complementary tool to tissue biopsy for oncology, especially for longitudinal monitoring, resistance detection, and recurrence surveillance. He says advances in affordable sequencing and Synvenio’s multi-template rare-cell platform (cells, cfDNA, germline) can improve accuracy, but broad adoption still depends on stronger clinical utility evidence and reimbursement.

Main Topics: What liquid biopsy is and why it matters (Priority: 5/5): DeFusco defines liquid biopsy as analyzing blood, urine, or other non-tissue samples to detect cancer-related signals, positioning it as a complementary, dynamic alternative to static tissue biopsy. Technological advances enabling the field (Priority: 5/5): The conversation highlights the drop in sequencing costs and improved usability of sequencing platforms as key drivers that made liquid biopsy more accessible and scalable. Synvenio’s multi-template detection strategy (Priority: 5/5): Synvenio sequences germline, circulating tumor cells/cells, and cell-free DNA together to improve specificity, reduce irrelevant calls, and capture different disease signals over time. Challenges of rare-cell enrichment and assay compatibility (Priority: 4/5): A major technical barrier is isolating rare cells without bias and producing material pure enough for downstream sequencing or PCR; Synvenio claims its platform addresses both. Clinical use cases across the cancer journey (Priority: 5/5): The platform is framed as useful for initial staging support, monitoring treatment response, identifying resistance mutations, and post-treatment surveillance for recurrence. Validation, clinical utility, and reimbursement (Priority: 4/5): DeFusco stresses that payer adoption requires stronger clinical utility data and more trials, not just concordance studies or analytical validity. Synvenio products and trial programs (Priority: 3/5): The company offers testing services and products such as cleared ID and NKVU, and is running or supporting cancer studies in breast, colorectal, prostate, and lung cancer.

Key Arguments: Liquid biopsy should be viewed as complementary to tissue biopsy, not a replacement, because tissue offers a one-time snapshot while blood enables longitudinal monitoring. Affordable sequencing platforms were the biggest technological enabler of the liquid biopsy boom, reducing the barrier from millions of dollars to roughly the low hundreds of thousands. Using multiple templates simultaneously—germline DNA, circulating tumor cells, and cell-free DNA—yields a more complete and safer interpretation than relying on a single signal source. Rare-cell enrichment is difficult because selection bias can miss relevant cells or states, especially those undergoing transition toward metastatic behavior. Synvenio claims its enrichment plus sequencing workflow is compatible with downstream sequencing/PCR without needing amplification of results. Liquid biopsy can support several stages of care: diagnosis/staging, treatment response monitoring, resistance detection, and recurrence surveillance. Clinical utility, not just analytical performance, is the main hurdle to reimbursement; payers want evidence the test changes treatment and improves outcomes. The field needs more clinical trials similar to therapeutic development to demonstrate real-world value in patient care. Synvenio is funding its own validation work and says it has already analyzed over 15,000 samples, using case-control sequencing to separate machine noise from biological signal. The company expects liquid biopsy to become mainstream within 5 to 10 years as early adopters demonstrate practical clinical benefit.

Data Points: Sequencer price range: $100,000 to $200,000 - Cost of lower-cost sequencing platforms that helped accelerate liquid biopsy adoption. Previous sequencer cost: Several million dollars - Approximate cost of sequencing devices just a few years earlier. Clinical studies funding raised: $25.5 million - Amount Synvenio raised last year to support trials and development. Samples analyzed: Better part of 15,000 samples - Synvenio’s reported sample volume used to distinguish machine noise from biological signal. Cancer types targeted in testing services: 4 primary focus areas - Breast, colorectal, prostate, and to a lesser degree lung cancer. Liquid biopsy adoption timeline: 5 to 10 years - DeFusco’s estimate for when liquid biopsy may become mainstream.

Pivotal Quotes: "I happen to view that liquid biopsy is complementary to tissue biopsy." — Andre DeFusco: He explains Synvenio’s stance that liquid biopsy adds value over time rather than replacing tissue sampling. "We actually sequence three templates simultaneously." — Andre DeFusco: He describes Synvenio’s multi-template approach using germline DNA, circulating tumor cells, and cell-free DNA. "I think it is a fundamental shift in how patients are diagnosed." — Andre DeFusco: He emphasizes the broader impact he expects liquid biopsy to have on oncology care.

Implications: The interview suggests liquid biopsy is moving from promising technology to practical oncology tool, but widespread use will depend on proof of clinical utility, workflow integration, and payer acceptance. If Synvenio’s approach holds up, blood-based monitoring could meaningfully reshape cancer care.